- Oggetto:
- Oggetto:
The molecular basis of Neurological therapies
- Oggetto:
The molecular basis of Neurological therapies
- Oggetto:
Academic year 2023/2024
- Course ID
- BIO0216A Pds 306-TB
- Teacher
- Tiziana Enrica Mongini (Lecturer)
- Degree course
- [0101M22] Molecular Biotechnology
- Year
- 2nd year
- Teaching period
- First semester
- Type
- Related or integrative
- Credits/Recognition
- 3
- Course disciplinary sector (SSD)
- MED/26 - neurology
- Delivery
- Formal authority
- Language
- English
- Attendance
- Obligatory
- Type of examination
- Written
- Type of learning unit
- modulo
- Modular course
- THERAPEUTIC BIOTECHNOLOGY (BIO0216 Pds 306-TB)
- Oggetto:
Sommario del corso
- Oggetto:
Course objectives
-
To learn the pathological and molecular basis of the wide spectrum of disorders affecting the central and peripheral nervous system;
- to inform about the rules and options for research on rare diseases
-
to examine the status of art of consolidated therapeutical protocols;
-
to explore the new perspectives and the research challenges of upcoming new therapeutical approaches
-
- Oggetto:
Results of learning outcomes
to be able to undestand the modern research approaches to therapies for several complex neurological disorders (i.e., neurodegeneration, genetic diseases, metabolica diseases) in the light of the new technologies
to raise the attention and interest on rare diseases
to suggest new reasearch approaches for neurological orphan diseases
- Oggetto:
Program
Neurological disorders: classification and pathogenetic mechanisms
Rare diseases : definitions and regulatory rules
Old and new therapies in neurology : general overview on drugs and beyond: substrate modulation, immunomodulatiom, cell therapies, enzymatic therapies, gene therapies
State of the art for: genetic neuromuscular diseases (neuropathies, muscular dystrophies , spinal muscular atrophy), mitochondrial disorders, trinucleotide repeat expansion diseases,
neurometabolic diseases (leukodystrophies, lysosomal diseases), autoimmune diseases
(MS, myastenia gravis), neurodegenerative disorders (ALS, PD, dementias), ultra rare diseases
Future developments next to come or just on the horizon- Oggetto:
Course delivery
Frontal lessons supported by slides; clinical cases presentation; questions and answers
- Oggetto:
Learning assessment methods
Written examination, with ten open questions (three points each, maximum score 30); oral integration or alternative oral examination may be required
Suggested readings and bibliography
- Oggetto:
A complete list of references including most recent reviews and original papers on the covered topics will be provided at the end of the course
- Enroll
- Open
- Oggetto: